



Pharmacy Benefit Manager Public Transparency Report - 2020 Data

07/30/2021

Table of Contents

Overview of 2021 Pharmacy Benefit Manager Reporting Process.....	4
Reporting process.....	4
Summary of Responses from PBMs.....	4
Data Limitations.....	4
Definitions of Terms Used in Public PBM Transparency Reports.....	5
Public Transparency Reports as Submitted by PBMs.....	6

2021 Pharmacy Benefit Manager Transparency Reporting

Minn. Stat. § 62W.06, subd. 2 requires all licensed pharmacy benefit managers to submit to the Department of Commerce a transparency report containing both aggregate and claims level data for business from the prior calendar year. Commerce is required to publish the public data contained in PBM transparency reporting on its website.

Reporting process

The Department provided all licensed entities instructions and templates for aggregate, claims level data, and public reporting.

PBMs were required to submit transparency reporting information to Commerce by June 1, 2021.¹ The Department requested that PBMs submit all three completed templates; however, due to the varying nature of PBM business models and contracts, a given PBM may not be responsible for submitting a full report. As such, PBMs were given an option to submit “zero” reports when applicable. New this year, Commerce asked PBMs claiming to be exempt from all reporting requirements to submit a written rationale for the basis of that claim.

A summary of the types of reports received by the Department are shown in the table at right.

The data published in the attached public reports is drawn from the aggregate report submitted by the each PBM, except data that would be considered trade secret under Minn. Stat. § 13.37. As required by law, the public reports do not contain any information such as claims level data that could lead to identification of a plan sponsor, and to further protect plan sponsor identity, the reports do not include the name of the PBMs submitting them.

Summary of responses from PBMs	
Total licensed PBMs	46
Claims level reports submitted	15
Aggregate reports submitted	18
Public reports submitted	19
PBMs submitting at least one 'zero report' template	16
PBMs claiming exemption from reporting requirements	18
PBMs not responding to Commerce	0

Data limitations

- PBMs were given instructions regarding units, rounding, and calculated fields, but the Department cannot guarantee full compliance with the reporting instructions.
- The data in this report has not been independently audited.
- While the Department provided a data dictionary to each PBM, some PBMs may have relatively small variations in how they calculated amounts based on their own internal definitions of a given term.
- The public reports that follow in this document are as submitted by the PBMs. Commerce has not vetted, modified, or reformatted any of the data.

¹ Minn. Stat. § 62W.06 sets the annual deadline for reporting as June 1. Last year, the reporting deadline was extended to October 1, due to extenuating circumstances related to COVID-19. The guidance document from the Department is accessible at <https://mn.gov/commerce-stat/pdfs/regulatory-guidance-20-28.pdf>.

Definitions of terms used in PBM public transparency report

WAC

The aggregate wholesale acquisition cost (WAC) of a given drug from the drug's manufacturer (does not include discounts or rebates).

Net WAC

WAC minus any rebates and other fees paid to the PBM with associated claims.

Rebates

Defined in Minn. Stat. § 62W.02 Subd. 17 as all price concessions paid by a drug manufacturer to a pharmacy benefit manager or plan sponsor, including discounts and other price concessions that are based on the actual or estimated utilization of a prescription drug. Rebates also include price concessions based on the effectiveness of a prescription drug as in a value-based or performance-based contract.

Other fees and payments

Any fees and payments, other than those defined as rebates, associated with the pharmaceutical claims in the given category from any source.

Total Rebates and Other Fees and Payments

Calculated as a sum of *total rebates* and *other fees and payments*

Total Rebates and Other Fees and Payments – Non Plan Sponsor

Total amount of rebates and other fees and payments except those that come directly from plan sponsors

Retained Rebates and Other Fees and Payments – Non Plan Sponsor

Total amount of rebates and other fees and payments except those directly from a plan sponsor that are retained by the PBM as revenue for services provided

Retained Rebates and Other Fees and Payments Percentage – Non Plan Sponsor

Calculated as a ratio of *retained rebates and other fees and payments* to *total rebates and other fees and payments*

Therapeutic Category

The grouping of drugs based on similar characteristics such as chemical structure, mechanism of action, or disease treated. PBMs were instructed use the US Pharmacopeia (USP) classification system and report drug groupings at the category level.

Plan Sponsor

A group purchaser as defined under Minn. Stat. § 62J.03; an employer in the case of an employee health benefit plan established or maintained by a single employer; or an employee organization in the case of a health plan established or maintained by an employee organization, an association, joint board trustees, a committee, or other similar group that establishes or maintains the health plan. This term includes a person or entity acting for a pharmacy benefit manager in a contractual or employment relationship in the performance of pharmacy benefit management. Plan sponsor does not include the Minnesota Department of Human Services.

Data for Publication on Commissioner Website

Masked PBM ID

2AY6SEPEK2

Data Period

CY2020

Retained Rebates and Other Fees and Payments

Percentage Across All Plan Sponsors

Highest	Lowest	Mean
100%	100%	100%

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	4,987,641	641,681	-	641,681	641,681	641,681	100%	4,345,960

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
ANALGESICS - OPIOID	\$1,558,256	1,223,444
ANTICONVULSANTS	\$578,728	556,791
NEUROMUSCULAR AGENTS	\$482,518	482,518
DERMATOLOGICALS	\$395,693	383,655
ASTHMATIC AND BRONCHODILATOR AGENTS	\$304,652	208,891
ANALGESICS - ANTI-INFLAMMATORY	\$200,570	200,570
ANTIDEPRESSANTS	\$168,031	162,172
ANTICOAGULANTS	\$122,948	79,711
MUSCULOSKELETAL THERAPY AGENTS	\$120,068	118,177
MIGRAINE PRODUCTS	\$116,746	86,627

Data for Publication on Commissioner Website

Masked PBM ID

43ELG4VCLZ

Data Period

CY2020

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0	0	0

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
\$	575,000 \$	47,000 \$	17,000.00 \$	66,000.00 \$	47,000.00 \$	- \$	-	\$ 550,000.00

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Analgesics	\$ 147,000	\$ 138,000
Sleep Disorder Agents	\$ 54,000	\$ 53,000
Antiparasitics	\$ 51,000	\$ 51,000
Anticonvulsants	\$ 44,000	\$ 43,000
Antivirals	\$ 40,000	\$ 38,000
Anesthetics	\$ 37,000	\$ 36,000
Respiratory Tract/Pulmonary Agents	\$ 33,000	\$ 26,000
Central Nervous System Agents	\$ 25,000	\$ 21,000
Anti-Addiction/Substance Abuse Treatment Agents	\$ 21,000	\$ 20,000
Antidepressants	\$ 19,000	\$ 20,000

Data for Publication on Commissioner Website

Masked PBM ID

65UA00HHAS

Data Period

CY2020

Retained Rebates and Other Fees and Payments

Percentage Across All Plan Sponsors

Highest	Lowest	Mean
N/A	N/A	N/A

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$ 74,903,000.00	\$ 6,654,000.00	0	6654000	0	0	0 \$ 68,249,000.00

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 9,329,000.00	\$ 7,700,000.00
Blood Glucose Regulators	\$ 4,985,000.00	\$ 3,483,000.00
Central Nervous System Agents	\$ 3,283,000.00	\$ 2,534,000.00
Respiratory Tract/ Pulmonary Agents	\$ 2,413,000.00	\$ 1,374,000.00
Respiratory Tract/ Pulmonary Agents	\$ 2,087,000.00	\$ 1,231,000.00
Blood Products and Modifiers	\$ 653,000.00	\$ 555,000.00
Antimigraine Agents	\$ 450,000.00	\$ 353,000.00
Antineoplastics	\$ 317,000.00	\$ 310,000.00
Hormonal Agents, Stimulant/Replacement/ Modifyii	\$ 674,000.00	\$ 310,000.00
Ophthalmic Agents	\$ 272,000.00	\$ 232,000.00

Data for Publication on Commissioner Website
 Masked PBM ID
 Data Period

AN25LHY62J
 CY2020

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0	0	0

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$ 1,308,000.00	\$ -	\$ -	\$ -	\$ -	\$ -	-	\$ 1,308,000.00

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Analgesics	\$ 878,000.00	\$ 878,000.00
Anesthetics	\$ 10,000.00	\$ 10,000.00
Antibacterials	\$ 1,000.00	\$ 1,000.00
Anticonvulsants	\$ 94,000.00	\$ 94,000.00
Antidepressants	\$ 92,000.00	\$ 92,000.00
Antidotes, Deterrents, and Toxicologic Agents	\$ 3,000.00	\$ 3,000.00
Antiemetics	\$ 18,000.00	\$ 18,000.00
Antimigraine Agents	\$ 33,000.00	\$ 33,000.00
Antimyasthenic Agents	\$ 13,000.00	\$ 13,000.00
Antiparkinson Agents	\$ 25,000.00	\$ 25,000.00
Antispasticity Agents	\$ 3,000.00	\$ 3,000.00
Blood Glucose Regulators	\$ 2,000.00	\$ 2,000.00
Blood Products and Modifiers	\$ 26,000.00	\$ 26,000.00
Cardiovascular Agents	\$ 1,000.00	\$ 1,000.00
Central Nervous System Agents	\$ 3,000.00	\$ 3,000.00
Dermatological Agents	\$ 41,000.00	\$ 41,000.00
Gastrointestinal Agents	\$ 28,000.00	\$ 28,000.00
Genetic or Enzyme or Protein Disorder: Replacement, Modifiers, Treatment	\$ 3,000.00	\$ 3,000.00
Ophthalmic Agents	\$ 11,000.00	\$ 11,000.00
Otic Agents	\$ 2,000.00	\$ 2,000.00
Respiratory Tract/ Pulmonary Agents	\$ 8,000.00	\$ 8,000.00
Sleep Disorder Agents	\$ 10,000.00	\$ 10,000.00
Miscellaneous	\$ 3,000.00	\$ 3,000.00

Data for Publication on Commissioner Website

Masked PBM ID

HQKKYL2T23

Data Period

CY2020

**Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors**

Highest	Lowest	Mean
N/A	N/A	N/A

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$ 74,903,000.00	\$ 6,654,000.00	0	6654000	0	0	0 \$ 68,249,000.00

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 9,329,000.00	\$ 7,700,000.00
Blood Glucose Regulators	\$ 4,985,000.00	\$ 3,483,000.00
Central Nervous System Agents	\$ 3,283,000.00	\$ 2,534,000.00
Respiratory Tract/ Pulmonary Agents	\$ 2,413,000.00	\$ 1,374,000.00
Respiratory Tract/ Pulmonary Agents	\$ 2,087,000.00	\$ 1,231,000.00
Blood Products and Modifiers	\$ 653,000.00	\$ 555,000.00
Antimigraine Agents	\$ 450,000.00	\$ 353,000.00
Antineoplastics	\$ 317,000.00	\$ 310,000.00
Hormonal Agents, Stimulant/Replacement/ Modifyii	\$ 674,000.00	\$ 310,000.00
Ophthalmic Agents	\$ 272,000.00	\$ 232,000.00

Data for Publication on Commissioner Website

Masked PBM ID

LLB4W9NRS8

Data Period

CY2020

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
82	0	24

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	1173647000	157794000	1073458000	1231261000	160570000	3367000	9.44	-57621000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	243560000	-27013000
Blood Glucose Regulators	170096000	-43372000
Respiratory Tract/ Pulmonary Agents	105271000	-11036000
Antivirals	84981000	1924000
Central Nervous System Agents	82316000	-571000
Antineoplastics	70012000	-3163000
Unclassified	54185000	-1345000
Antipsychotics	40254000	427000
Blood Products and Modifiers	39396000	218000
Antidepressants	28268000	685000

Data for Publication on Commissioner Website

Masked PBM ID

P333HYNFGD

Data Period

CY2020

Retained Rebates and Other Fees and Payments

Percentage Across All Plan Sponsors

Highest	Lowest	Mean
43%	0%	7%

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$90,420,411	\$16,441,557	\$1,871,675	\$26,556,499	\$16,600,946	(\$516,725)	0.00%	\$63,863,912

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
IMMUNOLOGICAL AGENTS	\$15,794,161	\$9,178,823
BLOOD GLUCOSE REGULATORS	\$10,239,827	\$4,481,511
RESPIRATORY TRACT/PULMONARY AGENTS	\$6,657,849	\$4,874,820
ANTIVIRALS	\$5,944,651	\$5,612,294
CENTRAL NERVOUS SYSTEM AGENTS	\$5,318,617	\$4,184,025
ANTIDIABETICS	\$5,200,231	\$2,239,164
ANALGESICS-ANTI-INFLAMMATORY	\$5,052,765	\$2,905,254
DERMATOLOGICAL AGENTS	\$4,976,542	\$2,921,628
ANTINEOPLASTICS	\$3,054,935	\$3,009,562
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFY	\$2,528,193	\$2,372,074

Data for Publication on Commissioner Website

Masked PBM ID

RLXV57H0E

Data Period

CY2020

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
100	0	25

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$1,007,906,000	\$16,598,000	\$516,000	\$17,114,000	\$17,114,000	\$516,000	3%	\$990,792,000

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$221,859,000	\$218,404,000
Blood Glucose Regulators	\$163,559,000	\$156,500,000
Respiratory Tract/Pulmonary Agents	\$89,883,000	\$87,902,000
Antineoplastics	\$81,727,000	\$81,682,000
Central Nervous System Agents	\$72,823,000	\$71,359,000
Antivirals	\$53,784,000	\$53,354,000
Blood Products and Modifiers	\$47,531,000	\$46,830,000
Cardiovascular Agents	\$29,994,000	\$29,653,000
Dermatological Agents	\$25,582,000	\$25,431,000
Antidepressants	\$21,861,000	\$21,745,000

Data for Publication on Commissioner Website
 Masked PBM ID
 Data Period

RRWDAAV66U
 CY2020

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors Highest 100 Lowest 100 Mean 100

Totals During Data Period WAC 443379 Rebates 39444 Other Fees and Payments 2922 Total Rebates and Other Fees and Payments 42367 Total Rebates and Other Fees and Payments - Non Plan Sponsor 0 Retained Rebates and Other Fees and Payments - Non Plan Sponsor 0 Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor 0 Net WAC AWP 401013

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC AWP	net WAC AWP
CARDIOVASCULAR AGENTS	62878	62878
RESPIRATORY TRACT/ PULMONARY AGENTS	42119	42119
ANTI-ADDICTION/ SUBSTANCE ABUSE TREATMENT AGENTS	33152	33152
INSULINS	32461	14361
ANXIOLYTICS	30073	30073
ANTIVIRALS, HIV-SPEC, NUCLEOSIDE-NUCLEOTIDE ANALOG	24318	24318
CENTRAL NERVOUS SYSTEM AGENTS	21519	21519
BLOOD GLUCOSE REGULATORS	20931	16377
DIRECT FACTOR XA INHIBITORS	20590	15702
ANTIPARKINSONISM DRUGS,OTHER	20187	16509

Data for Publication on Commissioner Website

Masked PBM ID

WMUPH5XT70

Data Period

CY2020

Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors

Highest	Lowest	Mean
0%	0%	0%

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$ 238,503.50	\$ 1,633.80	\$ 27,720.00	\$ 29,353.80	\$ -	\$ -	-	\$ 209,149.70

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Products Without a USP Category	\$ 68,878.31	\$ 68,378.31
Central Nervous System Agents	\$ 36,568.89	\$ 32,433.21
Analgesics	\$ 30,865.98	\$ 21,811.52
Respiratory Tract/ Pulmonary Agents	\$ 17,163.42	\$ 15,124.36
Antidepressants	\$ 14,888.55	\$ 12,788.55
Antispasticity Agents	\$ 12,909.79	\$ 11,769.79
Dermatological Agents	\$ 11,177.86	\$ 9,877.86
Antiemetics	\$ 8,133.11	\$ 7,653.11
Blood Products and Modifiers	\$ 7,682.55	\$ 6,804.71
Skeletal Muscle Relaxants	\$ 6,312.24	\$ 3,972.24

Note: Products Without a USP Category were related to compound medications.

Data for Publication on Commissioner Website

Masked PBM ID

XS1BPIR4R9

Data Period

CY2020

**Retained Rebates and Other Fees and Payments
Percentage Across All Plan Sponsors**

Highest	Lowest	Mean
N/A	N/A	N/A

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$ 74,903,000.00	\$ 6,654,000.00	0	6654000	0	0	0 \$ 68,249,000.00

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$ 9,329,000.00	\$ 7,700,000.00
Blood Glucose Regulators	\$ 4,985,000.00	\$ 3,483,000.00
Central Nervous System Agents	\$ 3,283,000.00	\$ 2,534,000.00
Respiratory Tract/ Pulmonary Agents	\$ 2,413,000.00	\$ 1,374,000.00
Respiratory Tract/ Pulmonary Agents	\$ 2,087,000.00	\$ 1,231,000.00
Blood Products and Modifiers	\$ 653,000.00	\$ 555,000.00
Antimigraine Agents	\$ 450,000.00	\$ 353,000.00
Antineoplastics	\$ 317,000.00	\$ 310,000.00
Hormonal Agents, Stimulant/Replacement/ Modifiers	\$ 674,000.00	\$ 310,000.00
Ophthalmic Agents	\$ 272,000.00	\$ 232,000.00

Data for Publication on Commissioner Website

Masked PBM ID

XWONB73J30

Data Period

CY2020

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	20%	0%	9%

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$ 108,197,907	\$ 20,939,211	\$ 1,032,099	\$ 21,971,310	\$ 20,939,211	\$ 4,187,856	20%	\$ 86,226,597

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
IMMUNOLOGICAL AGENTS > IMMUNE SUPPRESSANTS	\$ 20,689,751	\$ 14,060,642
DERMATOLOGICAL AGENTS > DERMATOLOGICAL AGENTS	\$ 10,925,312	\$ 8,548,295
BLOOD GLUCOSE REGULATORS > INSULINS	\$ 6,881,689	\$ 3,724,043
BLOOD GLUCOSE REGULATORS > ANTIDIABETIC AGENTS	\$ 6,114,721	\$ 3,658,988
CENTRAL NERVOUS SYSTEM AGENTS > MULTIPLE SCLEROSIS AGENTS	\$ 5,572,564	\$ 4,792,684
ANTINEOPLASTICS > MOLECULAR TARGET INHIBITORS	\$ 4,522,253	\$ 4,515,941
RESPIRATORY TRACT/PULMONARY AGENTS > RESPIRATORY TRACT AGENTS, OTHER	\$ 3,510,400	\$ 2,523,715
HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS) > ESTROGENS	\$ 2,775,870	\$ 2,654,135
CENTRAL NERVOUS SYSTEM AGENTS > ATTENTION DEFICIT HYPERACTIVITY DISORDER AGENTS, AMPHETAMINES	\$ 2,524,023	\$ 2,228,698
RESPIRATORY TRACT/PULMONARY AGENTS > CYSTIC FIBROSIS AGENTS	\$ 2,313,677	\$ 2,310,376

Data for Publication on Commissioner Website

Masked PBM ID

Y123W5GCPR

Data Period

CY2020

Retained Rebates and Other Fees and Payments

Percentage Across All Plan Sponsors

Highest

0%

Lowest

0%

Mean

0%

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$7,189,009	\$444,956	\$113,432	\$558,389	\$444,956	\$0	0%	\$6,630,621

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Immunological Agents	\$1,955,647	\$1,774,361
Antineoplastics	\$1,059,528	\$1,055,330
Products Without a USP Category	\$1,027,371	\$1,000,055
Respiratory Tract/Pulmonary Agents	\$581,896	\$507,123
Central Nervous System Agents	\$569,742	\$555,913
Blood Glucose Regulators	\$476,875	\$351,708
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Tr	\$223,048	\$215,931
Dermatological Agents	\$204,819	\$193,309
Cardiovascular Agents	\$131,799	\$107,626
Blood Products and Modifiers	\$131,114	\$115,393
Antidepressants	\$97,636	\$79,823

Data for Publication on Commissioner Website
 Masked PBM ID
 Data Period

YM7P1OVQZC
 CY2020

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors
 n/a
 i) The value of rebates received is provided back to sponsors through discounted pricing.

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
i) The value of rebates received is provided back to sponsors through discounted pricing.	\$1,731,868.49	\$25,014.83	(\$17,060.52)	\$7,954.31	\$7,954.31	\$0.01	0.0%	\$1,723,914.18

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Analgesics	\$507,852.34	\$503,723.33
Respiratory Tract/Pulmonary Agents	\$283,774.11	\$281,388.52
Anticonvulsants	\$152,685.99	\$154,514.36
Antidepressants	\$109,644.59	\$109,821.12
Antimigraine Agents	\$100,067.78	\$97,890.89
Anesthetics	\$66,635.33	\$66,805.02
Blood Glucose Regulators	\$59,063.58	\$56,840.05
Immunological Agents	\$52,018.08	\$52,018.08
Blood Products and Modifiers	\$47,042.85	\$46,778.31
Ophthalmic Agents	\$45,798.37	\$43,930.26

Data for Publication on Commissioner Website

Masked PBM ID

Data Period

YNVDSNGF4

CY2020

Retained Rebates and Other Fees and Payments Percentage Across All Plan Sponsors	Highest	Lowest	Mean
	100.00%	0.26%	50.00%

Totals During Data Period	WAC	Rebates	Other Fees and Payments	Total Rebates and Other Fees and Payments	Total Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments - Non Plan Sponsor	Retained Rebates and Other Fees and Payments Percentage - Non Plan Sponsor	Net WAC
	\$101,382,570.05	\$30,617,090.92	\$76,193,182.89	\$106,810,273.81	\$30,907,292.01	\$1,057,774.31	3.42%	-\$5,427,703.76

Top 10 Categories by Spend - Descending Order

Therapeutic Category	WAC	net WAC
Blood Glucose Regulators	18,018,668.83	-9,380,676.39
Central Nervous System Agents	12,937,538.63	-4,347,747.17
Respiratory Tract/Pulmonary Agents	11,461,775.56	-4,993,924.63
Blood Products/Modifiers/Volume Expanders	8,103,361.86	-1,808,127.26
Cardiovascular Agents	6,209,288.16	2,273,777.50
Antidepressants	4,248,803.82	1,745,299.78
Anticonvulsants	4,152,776.77	976,828.92
Antibacterials	3,709,462.00	2,191,393.73
Anti-Addiction/Substance Abuse Treatment Agents	3,594,324.13	1,180,824.89
Hormonal Agents, Stimulant/Replacement/Modifying (Sex Horm)	3,463,051.64	464,732.78